American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: http://www.sciepub.com/journal/ajmsm Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medical Sciences and Medicine. 2014, 2(2), 44-47
DOI: 10.12691/ajmsm-2-2-4
Open AccessCase Report

Rapid Antidepressant Action of Ketamine in Psychiatric Patients with Suicidality - a Case Series

Rajnish Raj1, and Raj Kumar2

1Department of Psychiatry, Govt. Medical College & Rajindra Hospital, Patiala, INDIA

2Department of Pharmacology, Guru Gobind Singh Medical College & Hospital (Baba Farid University of Health Sciences), Faridkot, INDIA

Pub. Date: April 21, 2014

Cite this paper:
Rajnish Raj and Raj Kumar. Rapid Antidepressant Action of Ketamine in Psychiatric Patients with Suicidality - a Case Series. American Journal of Medical Sciences and Medicine. 2014; 2(2):44-47. doi: 10.12691/ajmsm-2-2-4

Abstract

Ketamine, a non-competitive NMDA receptor antagonist with rapid antidepressant action, is a novel approach in modulating glutamate receptors for management of treatment-resistant major depressive disorder. It clinically engenders meaningful advances in depression therapeutics. This case series highlights the role of low dose intravenous ketamine infusion i.e., 0.5 mg/kg dissolved in 100 ml normal saline and given over a period of 40 minutes in patients of depression who were contemplating suicide.

Keywords:
Ketamine N-methyl D-Aspartate antagonist (NMDA) major depressive disorder (MDD) mammalian target of rapamycin (mTOR) brain derived neurotrophic factor (BDNF) Eukaryotic Elongation Factor 2 (eEF 2) kinase

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  The World Health Report, Mental Health: New Understanding, New Hope, Geneva, World Health Organization, 2001.
 
[2]  Stahl, S.M, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. Cambridge: Cambridge University Press; 2008. pp 520-521.
 
[3]  Hashimoto, K, Emerging role of glutamate in the pathophysiology of major depressive disorder, Brain Res Rev, 61. 105-123. 2009.
 
[4]  Sanacora, G., Zarate, C.A., Krystal, J.H. and Manji, H.K, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders, Nat Rev Drug Discov, 7. 426-437. 2008.
 
[5]  Liebrenz, M., Borgeat, A., Leisinger, R. and Stohler, R, Intravenous ketamine therapy in a patient with a treatment-resistant major depression, Swiss Med Wkly, 137. 234-236. 2007.
 
[6]  Machado-Vieira, R., Salvadore, G., Diazgranados, N. and Zarate, C.A. Jr, Ketamine and the next generation of antidepressants with a rapid onset of action, Pharmacol Ther, 123. 143-150. 2009.
 
[7]  Price, R.B., Nock, M.K., Charney, D.S. and Mathew, S.J, Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression, Biol Psychiatry, 66. 522-526. 2009.
 
[8]  Harihar, C., Dasari, P. and Srinivas, J.S, Intramuscular ketamine in acute depression: A report on two cases, Indian J Psychiatry, 55. 186-188. 2013.
 
[9]  Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R. and Charney, D.S, Antidepressant effects of ketamine in depressed patients, Biol Psychiatry, 47. 351-354. 2000.
 
[10]  Aan het Rot, M., Collins, K.A., Murrough, J.W., Perez, A.M., Reich, D.L., Charney, D.S. el al., Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression, Biol Psychiatry, 67. 139-145. 2010.
 
[11]  Murrough, J.M., Losifescu, D.V., Chang, L.C., Al Jurdi, R.K. et al., Antidepressant efficacy of ketamine in treatment-resistant major depression: A two site randomized controlled trial, Am J Psychiatry, 170. 1134-1142. 2013.
 
[12]  Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A. et al., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch Gen Psychiatry, 63. 856-864. 2006.
 
[13]  Rao, T.S.S. and Andrade, C, Innovative approaches to treatment – refractory depression: The ketamine story, Indian J Psychiatry, 52. 97-99. 2010.
 
[14]  Mathew, S.J., Shah, A., Lapidus, K., Clark, C. et al., Ketamine for treatment –resistant unipolar depression: current evidence, CNS Drugs, 26. 189-204. 2012.
 
[15]  Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., et al., A randomized add-on trial of N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression, Arch Gen Psychiatry, 67. 793-802. 2010.
 
[16]  Ramirez, D.M., Khvotchev, M., Trauterman, B. and Kavalali, E.T, Vti 1a identifies a vesicle pool preferentially recycles at rest and maintains spontaneous neurotransmission, Neuron, 73. 121-134. 2012.
 
[17]  Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F. et al., NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses, Nature, 475. 91-95. 2011.
 
[18]  Sutton, M.A. and Schuman, E.M, Dendritic protein synthesis, synaptic plasticity and memory, Cell, 127. 49-58. 2006.
 
[19]  Ege, T.K. and Lisa, M.M, Synaptic mechanisms underlying rapid antidepressant action of ketamine, Am J Psychiatry, 169. 1150-1156. 2012.
 
[20]  Li, N., Lee, B., Liu, R.J., Banasr, M. et al., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, 329. 959-964. 2010.
 
[21]  Olney, J., Labruyere, J. and Price, M.T, Pathological changes induced in cerebro-cortical neurons by phencyclidine related drugs, Sciences, 244. 1360-1362. 1989.
 
[22]  Higgins, G.A., Ballard, T.M., Huwyler, J., Kemp, J.A. and Gill, R, Evaluation of the NR2B selective NMDA receptor anatagonist R0 63-1908 on rodent behavior: evidence for involvement of NR2B NMDA receptors inhibition, Neuropharmacology, 44. 324-341. 2003.
 
[23]  Machado-Vieira, R., Yuan, P., Brutsche, N., Diazgranados, N., Luckenbaugh, D., Manji, H.K. et al., Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist, J Clin Psychiatry, 70. 1662-1666. 2009.
 
[24]  Haas, D.A. and Harper, D.G, Ketamine: a review of its pharmacologic properties and use in ambulatory anaesthesia, Anesth Prog, 39.61-68. 1992.
 
[25]  Anand, A., Charney, D.S., Oren, D.A. et al., Attenuation of the neuropsychiatric effects of ketamine with lamotrigine, Arch Gen Psychiatry, 57. 270-276. 2000.
 
[26]  Overall, J.E. and Gorham, D.R, The Brief Psychiatric Rating Scale (BPRS), Psychol Rep, 10. 799-812. 1962.
 
[27]  Montgomery, S.A. and Asberg, M, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134. 382-389. 1979.
 
[28]  Goodman, W.K., Price, L.H., Rasmssen, S.A. et al., The Yale- Brown Obsessive Compulsive Scale-I: Development, use and reliability, Arch Gen Psychiatry, 46. 1006-1011. 1989.
 
[29]  Bremner, J.D., Krystal, J.H., Putnam, F.W., Southwick, S.M. et al., Measurement of dissociative states with the Clinician- Administered Dissociative States Scale (CADSS), J Trauma Stress, 11. 125-136. 1998.